4.6 Article

Photon-tissue interaction model enables quantitative optical analysis of human pancreatic tissues

Journal

OPTICS EXPRESS
Volume 18, Issue 21, Pages 21612-21621

Publisher

OPTICAL SOC AMER
DOI: 10.1364/OE.18.021612

Keywords

-

Categories

Funding

  1. National Institutes of Health [NIH-CA-114542]
  2. National Pancreas Foundation
  3. Wallace H. Coulter Foundation
  4. U of M Comprehensive Cancer Center
  5. U of M Medical School

Ask authors/readers for more resources

A photon-tissue interaction (PTI) model was developed and employed to analyze 96 pairs of reflectance and fluorescence spectra from freshly excised human pancreatic tissues. For each pair of spectra, the PTI model extracted a cellular nuclear size parameter from the measured reflectance, and the relative contributions of extracellular and intracellular fluorophores to the intrinsic fluorescence. The results suggest that reflectance and fluorescence spectroscopies have the potential to quantitatively distinguish among pancreatic tissue types, including normal pancreatic tissue, pancreatitis, and pancreatic adenocarcinoma. (C) 2010 Optical Society of America

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

Stephan B. Dreyer, Rosie Upstill-Goddard, Viola Paulus-Hock, Clara Paris, Eirini-Maria Lampraki, Eloise Dray, Bryan Serrels, Giuseppina Caligiuri, Selma Rebus, Dennis Plenker, Zachary Galluzzo, Holly Brunton, Richard Cunningham, Mathias Tesson, Craig Nourse, Ulla-Maja Bailey, Marc Jones, Kim Moran-Jones, Derek W. Wright, Fraser Duthie, Karin Oien, Lisa Evers, Colin J. McKay, Grant A. McGregor, Aditi Gulati, Rachel Brough, Ilirjana Bajrami, Stephan Pettitt, Michele L. Dziubinski, Juliana Candido, Frances Balkwill, Simon T. Barry, Robert Grutzmann, Lola Rahib, Amber Johns, Marina Pajic, Fieke E. M. Froeling, Phillip Beer, Elizabeth A. Musgrove, Gloria M. Petersen, Alan Ashworth, Margaret C. Frame, Howard C. Crawford, Diane M. Simeone, Chris Lord, Debabrata Mukhopadhyay, Christian Pilarsky, David A. Tuveson, Susanna L. Cooke, Nigel B. Jamieson, Jennifer P. Morton, Owen J. Sansom, Peter J. Bailey, Andrew Biankin, David K. Chang

Summary: DDR deficiency and replication stress are independent of each other, offering opportunities for therapy in DDR-proficient PC and after platinum therapy. Patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors, including previously described molecular subtypes, and serve as a valuable model for studying novel therapeutic strategies targeting DDR and replication stress in PC.

GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer

Johann Gout, Lukas Perkhofer, Mareen Morawe, Frank Arnold, Michaela Ihle, Stephanie Biber, Sebastian Lange, Elodie Roger, Johann M. Kraus, Katja Stifter, Stephan A. Hahn, Andrea Zamperone, Thomas Engleitner, Martin Mueller, Karolin Walter, Eva Rodriguez-Aznar, Bruno Sainz Jr, Patrick C. Hermann, Elisabeth Hessmann, Sebastian Mueller, Ninel Azoitei, Andre Lechel, Stefan Liebau, Martin Wagner, Diane M. Simeone, Hans A. Kestler, Thomas Seufferlein, Lisa Wiesmueller, Roland Rad, Pierre-Olivier Frappart, Alexander Kleger

Summary: The study identified synergistic effects in inhibiting PARP, ATR, and DNA-PKcs that lead to synthetic lethality in ATM-deficient pancreatic ductal adenocarcinoma. Chemical inhibition of ATM sensitized human PDAC cells towards this combinatorial therapy, which was also found to overcome PARP inhibitor resistance. These findings suggest potential mutation-specific therapeutic strategies that may be applied through ATM inhibition regardless of genotype.
Article Gastroenterology & Hepatology

Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma

Robert C. Grant, Robert Denroche, Gun Ho Jang, Klaudia M. Nowak, Amy Zhang, Ayelet Borgida, Spring Holter, James T. Topham, Julie Wilson, Anna Dodd, Raymond Jang, Rebecca Prince, Joanna M. Karasinska, David F. Schaeffer, Yifan Wang, George Zogopoulos, Scott Berry, Diane Simeone, Daniel J. Renouf, Faiyaz Notta, Grainne O'Kane, Jennifer Knox, Sandra Fischer, Steven Gallinger

Summary: Patients with MMRD pancreatic cancer exhibit longer overall survival, distinct histopathological and genomic features, and may benefit from targeted therapies based on their unique genomic drivers.
Article Cell Biology

ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer

Vinee Purohit, Lidong Wang, Huibin Yang, Jiufeng Li, Gina M. Ney, Erica R. Gumkowski, Akash J. Vaidya, Annie Wang, Amit Bhardwaj, Ende Zhao, Igor Dolgalev, Andrea Zamperone, Ethan V. Abel, Marina Pasca Di Magliano, Howard C. Crawford, Daniel Diolaiti, Thales Y. Papagiannakopoulos, Costas A. Lyssiotis, Diane M. Simeone

Summary: The overexpression of ATDC in pancreatic cancer promotes tumor growth and metastasis by protecting cancer cells from ROS through stabilizing NRF2. This mechanism enhances chemoresistance and modulates redox balance in cancer cells.

GENES & DEVELOPMENT (2021)

Editorial Material Oncology

A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment

Rafael Winograd, Diane M. Simeone, Dafna Bar-Sagi

Summary: Immune checkpoint blockade has shown efficacy in multiple cancers, but further improvements are needed to increase response rates and achieve clinical efficacy in cold tumors. Mechanistic studies of tumor-specific immunosuppressive pathways can uncover biological barriers to immunotherapy and offer new therapeutic insights.

BRITISH JOURNAL OF CANCER (2021)

Article Cell Biology

A pan-cancer organoid platform for precision medicine

Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V. T. Catenacci, Jeremy Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen

Summary: A robust pan-cancer tumor organoid platform with chemically defined media has been established and neural-network-based high-throughput method has been demonstrated to predict patient-specific heterogeneity in drug responses. These resources are expected to accelerate the broad implementation of organoid models in precision medicine research and personalized therapeutic profiling programs.

CELL REPORTS (2021)

Letter Oncology

Proteome heterogeneity and malignancy detection in pancreatic cyst fluids

Sheng Pan, Randall E. Brand, Lisa A. Lai, David W. Dawson, Timothy R. Donahue, Stephen Kim, Natalia I. Khalaf, Mohamed O. Othman, William E. Fisher, Mary P. Bronner, Diane M. Simeone, Teresa A. Brentnall, Ru Chen

CLINICAL AND TRANSLATIONAL MEDICINE (2021)

Article Gastroenterology & Hepatology

Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detection Consortium

Tamas A. Gonda, James Farrell, Michael Wallace, Lauren Khanna, Eileen Janec, Richard Kwon, Michael Saunders, Uzma D. Siddiqui, Randall Brand, Diane M. Simeone

Summary: The adoption of a standardized EUS reporting template will improve consistency in clinical decision-making for individuals at risk of pancreatic cancer and provide complete and accurate reporting of pancreatic abnormalities. Standardization will also facilitate research and clinical trial design, allowing for comparison of results across different centers.

GASTROINTESTINAL ENDOSCOPY (2022)

Article Oncology

Cyst fluid metabolites distinguish malignant from benign pancreatic cysts

Jiaqi Shi, Zhujun Yi, Lin Jin, Lili Zhao, Alexander Raskind, Larisa Yeomans, Zeribe C. Nwosu, Diane M. Simeone, Costas A. Lyssiotis, Kathleen A. Stringer, Richard S. Kwon

Summary: (Iso)-butyrylcarnitine has the potential to accurately distinguish malignant from benign pancreatic cysts, with a diagnostic accuracy of 89%. Additionally, 5-oxoproline can differentiate mucinous from non-mucinous cysts with a diagnostic accuracy of 90%, better than glucose.

NEOPLASIA (2021)

Review Gastroenterology & Hepatology

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Laura D. Wood, Marcia Irene Canto, Elizabeth M. Jaffee, Diane M. Simeone

Summary: This review discusses the pathogenesis, early detection methods, and treatment considerations of pancreatic ductal adenocarcinoma (PDAC). Recent advances in understanding PDAC have led to significant improvements in detection and treatment, but coordinated efforts are needed to maximize clinical impact for patients and overall survival.

GASTROENTEROLOGY (2022)

Review Radiology, Nuclear Medicine & Medical Imaging

Standardization of MRI Screening and Reporting in Individuals With Elevated Risk of Pancreatic Ductal Adenocarcinoma: Consensus Statement of the PRECEDE Consortium

Chenchan Huang, Diane M. Simeone, Lyndon Luk, Elizabeth M. Hecht, Gaurav Khatri, Avinash Kambadakone, Hersh Chandarana, Justin M. Ream, Jessica N. Everett, Alexander Guimaraes, Joy Liau, Anil K. Dasyam, Carla Harmath, Alec J. Megibow

Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor survival rates. High-risk individuals are recommended to have regular screening with MRI and/or endoscopic ultrasound. The Pancreatic Cancer Early Detection (PRECEDE) Consortium aims to increase survival of PDAC by facilitating earlier diagnosis through standardized MRI screening and reporting.

AMERICAN JOURNAL OF ROENTGENOLOGY (2022)

Article Biochemistry & Molecular Biology

Functional and biological heterogeneity of KRASQ61 mutations

Minh Huynh, G. Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M. Carey, J. Nathaniel Diehl, Jonathan M. DeLiberty, Ryan D. Thurman, Adelaide R. Cooke, Craig M. Goodwin, Joshua H. Cook, Lin Lin, Andrew M. Waters, Naim U. Rashid, Emanuel F. Petricoin, Sharon L. Campbell, Kevin M. Haigis, Diane M. Simeone, Costas A. Lyssiotis, Adrienne D. Cox, Channing J. Der

Summary: Missense mutations at the three hotspots in RAS-Gly(12), Gly(13), and Gln(61) show differential distribution among the three RAS isoforms. KRAS(Q61) mutants exhibit various changes in morphology, growth transformation, effector signaling, and metabolism. Differences in biochemical, structural, and biological properties may explain the frequency variations. Targeting KRAS(Q61) mutant-specific signaling and cellular output may be a potential therapeutic strategy.

SCIENCE SIGNALING (2022)

Article Oncology

Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting

Jessica N. Everett, Shenin A. Dettwyler, Xiaohong Jing, Cody Stender, Madeleine Schmitter, Ariele Baptiste, Jennifer Chun, Emily A. Kawaler, Lauren G. Khanna, Seth A. Gross, Tamas A. Gonda, Nina Beri, Paul E. Oberstein, Diane M. Simeone

Summary: Integrating genetics into a multidisciplinary setting improves compliance with genetic testing for pancreatic ductal adenocarcinoma (PDAC) patients, reduces logistical barriers, and clarifies cancer risks for relatives.

CANCER MEDICINE (2023)

Article Oncology

DNMT3A/miR-129-2-5p/Rac1 Is an Effector Pathway for SNHG1 to Drive Stem-Cell-like and Invasive Behaviors of Advanced Bladder Cancer Cells

Jiheng Xu, Rui Yang, Jingxia Li, Lidong Wang, Mitchell Cohen, Diane M. Simeone, Max Costa, Xue-Ru Wu

Summary: The stem-cell-like behavior of cancer cells in bladder cancer plays a crucial role and its molecular basis remains incompletely defined. This study demonstrates that SNHG1 induces the formation of stem-cell-like spheres and invasion of bladder cancer cells by upregulating Rho GTPase, Rac1. SNHG1 binds to DNMT3A and represses the transcription of miR-129-2-5p, resulting in increased Rac1 protein levels. High expression of Rac1 is associated with poor prognosis in bladder cancer patients.

CANCERS (2022)

Article Gastroenterology & Hepatology

Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts

Sharon Pan, Lisa A. Lai, Diane M. M. Simeone, David W. W. Dawson, Yuanqing Yan, Tatjana Crnogorac-Jurcevic, Ru Chen, Teresa A. Brentnall

Summary: Proteomic and functional analysis of extracellular vesicles (EVs) released from pancreatic cancer cells and cancer-associated fibroblasts (CAFs) identified over 1400 nonredundant proteins involved in vesicle-mediated transport and exocytosis. Protein networks relevant to pancreatic tumorigenesis, such as epithelial-mesenchymal transition, complement, and coagulation components, were significantly enriched in EVs from cancer cells or CAFs, suggesting a potential role of EVs in mediating signals related to tumorigenesis and microenvironment interactions.

PANCREAS (2022)

No Data Available